ImmunoGen, Inc. Announces Genentech's Renewal of Technology Access Agreement
ImmunoGen, Inc. announced that Genentech has renewed the agreement that provides Genentech with certain rights to test and to use ImmunoGen's Tumor-Activated Prodrug (TAP) technology with Genentech therapeutic antibodies to specific targets. The original May 2000 agreement included a provision that allows Genentech to renew the agreement for one additional three-year term by payment of a $2 million technology access fee, which Genentech has now paid to ImmunoGen.
In May 2000, ImmunoGen and Genentech entered into a five-year agreement granting Genentech certain rights to test ImmunoGen's maytansinoid TAP technology with Genentech therapeutic antibodies to specific targets, and to license the right to use the technology to develop products on the terms defined in the agreement. Under this agreement, Genentech recently licensed the exclusive right to use ImmunoGen's technology with therapeutic antibodies to an undisclosed target.
ImmunoGen's TAP technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. The Company uses its TAP technology to develop its own products, and helps fund its product programs by selectively outlicensing its technology to other companies for use with their proprietary antibodies. In April 2005, Genentech licensed the right to use ImmunoGen's maytansinoid TAP technology with its therapeutic antibodies to an undisclosed target. Genentech also licensed the right to use ImmunoGen's technology with therapeutic antibodies to HER2 under a separate agreement.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous